A Hyderabad-based vaccine and pharmaceutical company announced the initiation of a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India.
This early-stage study’s results are expected to be available by February 2021.
Read More
![](https://covid19.healthcare.pro/wp-content/uploads/2020/11/hyderabad-2707439-1.jpg)